Related Experiment Video
Updated: Jul 22, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes
1Texas Children's Hospital Diabetes Care Center for Children and Adolescents, Department of Pediatrics, Baylor College of Medicine, Houston, USA. mhaymod@bcm.tmc.edu
Insights
Mini-dose glucagon injections effectively manage hypoglycemia in children with type 1 diabetes during illness. This approach helps stabilize blood glucose levels, allowing children to recover at home.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Type 1 diabetes management in children is challenging during gastroenteritis or reduced carbohydrate intake.
- Hypoglycemia is a common complication in these scenarios, requiring prompt intervention.
Purpose of the Study:
- To evaluate the efficacy of low-dose subcutaneous glucagon for managing impending or mild hypoglycemia in children with type 1 diabetes.
- To assess the safety and effectiveness of this intervention in a home-care setting.
Main Methods:
- A study analyzed 33 episodes of hypoglycemia in 28 children with type 1 diabetes and gastroenteritis.
- Dosing of subcutaneous glucagon was age-dependent, with adjustments for inadequate response.
- Patient self-monitoring of blood glucose and frequent physician contact were utilized.
Main Results:
- Glucagon administration significantly increased blood glucose levels from 3.44 to 8.11 mmol/l within 30 minutes.
- Retreatment was necessary in 14 children, and a third dose in four.
- Glucagon was well-tolerated, and 28 of 33 children recovered at home without hospitalization for hypoglycemia.
Conclusions:
- Subcutaneous mini-dose glucagon is an effective rescue therapy for hypoglycemia in pediatric type 1 diabetes.
- This method facilitates home management of hypoglycemia related to poor oral intake or gastroenteritis.
Objective:
Children with type 1 diabetes are frequently difficult to manage during times of gastroenteritis or poor oral intake of carbohydrates because of mild or impending hypoglycemia. The present study describes the effective use of small doses of subcutaneous glucagon in these children.
Research Design And Methods:
We analyzed 33 episodes of impending or mild hypoglycemia in 28 children (ages 6.6 +/- 0.7 years). All were healthy except for type 1 diabetes and an episode of gastroenteritis. Using a standard U-100 insulin syringe, children ages < or = 2 years received two "units" (20 microg) of glucagon subcutaneously and those ages >2 years received one unit/year of age up to 15 units (150 microg). If the blood glucose did not increase within 30 min, the initial dosage was doubled and given at that time. We used patients' self-glucose monitoring devices, aqueous glucagon, standard insulin syringes, and frequent phone contact with a physician and/or a diabetes nurse educator in this study.
Results:
Blood glucose was 3.44 +/- 0.15 mmol/l before and 8.11 +/- 0.72 mmol/l 30 min after glucagon. In 14 children, relative hypoglycemia recurred, requiring retreatment (3.48 +/- 0.18 to 6.94 +/- 0.72 mmol/l). In four children, a third dose was required. The glucagon was well tolerated In 28 of the 33 episodes of impending hypoglycemia, the children remained at home and fully recovered. Five children were taken to their local hospital because of concerns of dehydration or fever, but none for hypoglycemia.
Conclusions:
Mini-dose glucagon rescue, using subcutaneous injections, is effective in managing children with type 1 diabetes during episodes of impending hypoglycemia due to gastroenteritis or poor oral intake of carbohydrate.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Hypoglycemia

